Bryan K. S. Yeung
Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore
Associate Director, Malaria Program at Novartis Institute for Tropical Diseases
SINGAPOREInvolved in programme for antimalarial shown below
http://newdrugapprovals.org/2014/12/27/nitd609/Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria
Bryan
K. S. Yeung, et al
Journal of Medicinal Chemistry, 2010 , vol. 53, 14 p. 5155 – 5164
SINGAPORE FLAGProfile
Bryan K S Yeung - ResearchGate
www.researchgate.net/profile/Bryan_Yeung
Researcher » Bryan K S Yeung, Novartis, Novartis Institute for Tropical Diseases (NITD), Singapore, Medicinal Chemistry and Organic Chemistry.Bryan K S Yeung - Publications - ResearchGate
www.researchgate.net/profile/Bryan_Yeung/publications
Paul W Smith, Thierry T Diagana, Bryan K S Yeung. [Show abstract] [Hide abstract] ABSTRACT: SUMMARY The number of novel antimalarial candidates ...Bryan Yeung profiles | LinkedIn
https://www.linkedin.com/pub/dir/Bryan/Yeung
View the profiles of professionals named Bryan Yeung on LinkedIn. There are 16 professionals named Bryan Yeung, who use LinkedIn to exchange information, ...
The Novartis Institute for Tropical Disease (NITD) is a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.[1][2]
History and mission
NITD was founded in 2002 as a public-private partnership between Swiss-based pharmaceutical company Novartis and the Singapore Economic Development Board.[1]NITD states its goals are "to discover novel treatments and prevention methods for major tropical diseases." Their website states they hope to have at least two drug candidates going through clinical trials in patients by the year 2012.[2]
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic.[3]
Research
NITD is a small molecule drug discovery research institute.[1]Research is currently focused on three main diseases:[2]
NITD's research model relies on global partnership with other research institutes.[1] In 2008, NITD announced a 5-year collaborative research effort would be conducted in cooperation with the TB Alliance to develop new medicines for tuberculosis, including drug resistant tuberculosis.[4]
Education
In addition to research, NITD is engaged in educational activities. It runs a research-based Master of Science program in fields related to infectious diseases in cooperation with National University of Singapore, University of Basel and Swiss Tropical Institute.[5]NITD also supports training opportunities for post-graduate students and post-doctoral fellows.[2]
Fighting neglected infectious diseases
In developing countries where these diseases are endemic, Novartis will make treatments accessible to the communities that need them. NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board (EDB) in 2002. Since then, it has grown to more than 100 researchers and supporting staff. As a major center of excellence for drug discovery, NITD will offer exceptional teaching and training opportunities for post-doctoral fellows and graduate students.
Contact NITD
Novartis Institute for Tropical Diseases Pte. Ltd.
10 Biopolis Road
#05-01 Chromos
Singapore 138670
EARLIER
Research Scientist II
Exelixis Inc
• Design and synthesis of kinase inhibitors for use as anti-cancer agents
• Supervised an associate research scientist
The Scripps Research Institute
PostDoc, Chemistry
Synthesis and screening of a library of DNA binding agents based on analogs of distamycin A
Preparation of heterocyclic monomer building blocks for a library of DNA binding agents
Synthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents
Preparation of heterocyclic monomer building blocks for a library of DNA binding agents
Synthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents
References
- "About NITD". Novartis AG. 2008. Retrieved 2008-12-23.
- "Our mission". Novartis AG. 2008. Retrieved 2008-12-23.
- "Commitment to Patients Earns Novartis' Dr. Daniel Vasella B'nai B'rith International's Highest Award". PharmaLive. Canon Communications Pharmaceutical Media Group. 2008-12-15. Retrieved 2008-12-23.
Novartis has developed several programs aimed at enhancing affordability and access to treatment, including the Novartis Institute for Tropical Diseases, where Novartis researches novel treatments and prevention methods for neglected tropical diseases such as Dengue fever, and will make these available, without profit, to poor endemic countries.
- "Novartis symposium in Mozambique tackles emerging tuberculosis challenges" (media release). Basel, Switzerland: Novartis Global Communications. 2008-09-08. p. 5. Retrieved 2008-12-23.
One of the core missions of the NITD is its commitment to improving access to medicines and helping reduce the overall global TB disease burden. The NITD recently announced a five-year research collaboration with the TB Alliance to develop new medicines for TB, including drug-resistant strains.
- "Master of Science in infectious diseases, vaccinology and drug discovery". Novartis AG. 2008. Retrieved 2008-12-23.[dead link]
External links
Patents by Inventor Bryan K. S. Yeung
Application number: 20090062274
Abstract: The invention is
directed to Compounds of Formula I and pharmaceutically acceptable
salts or solvates thereof, as well as methods of making and using the
compounds.
Type:
Application
Filed:
October 9, 2006
Issued:
March 5, 2009
Assignee:
Exelixis, Inc
Inventors:
Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K.S. Yeung
SINGAPORE PICS
SINGAPORE PICS
No comments:
Post a Comment